Метформин в терапии COVID-19 у пациентов сахарным диабетом: польза или вред?

Метформин в терапии COVID-19 у пациентов сахарным диабетом: польза или вред?

Автор: Айтбаев Кубаныч Авенович, Мамутова Светлана Калиевна, Муркамилов Илхом Торобекович, Фомин Виктор Викторович, Кудайбергенова Индира Орозобаевна, Муркамилова Жамила Абдилалимовна, Юсупов Фуркат Абдулахатович

Журнал: Бюллетень науки и практики @bulletennauki

Рубрика: Медицинские науки

Статья в выпуске: 6 т.7, 2021 года.

Бесплатный доступ

Сахарный диабет является одним из наиболее частых сопутствующих заболеваний среди пациентов с коронавирусной болезнью 2019 (COVID-19), который может осложнить течение этой новой вирусной инфекции. В свою очередь, метформин - это антигипергликемический препарат с иммуномодулирующим действием, который снимает выраженное воспаление и уменьшает повреждение легочной ткани. Данный обзор имеет целью обобщить имеющиеся в литературе данные о возможности использования метформина, его эффективности и механизмах действия, при лечении COVID-19 у пациентов с сахарным диабетом.

Коронавирус, сахарный диабет, ковид-19, метформин

Короткий адрес: https://sciup.org/14121002

IDR: 14121002   |   DOI: 10.33619/2414-2948/67/25

Список литературы Метформин в терапии COVID-19 у пациентов сахарным диабетом: польза или вред?

  • Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., ... Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia // New England journal of medicine. 2020.
  • Park S. E. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) // Clinical and experimental pediatrics. 2020. V. 63. №4. P. 119. https://doi.org/10.3345/cep.2020.00493
  • (WHO) WHO. WHO Director-General"s opening remarks at the media briefing on COVID-19. 11 March 2020.
  • (WHO) WHO. Coronavirus disease (COVID-2019) situation reports.
  • Sanders J. M., Monogue M. L., Jodlowski T. Z., Cutrell J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review // Jama. 2020. V. 323. №18. P. 1824-1836. https://doi.org/1001/jama.2020.6019
  • Beigel J. H., Tomashek K. M., Dodd L. E., Mehta A. K., Zingman B. S., Kalil A. C., Lane H. C. Remdesivir for the treatment of Covid-19 // New England Journal of Medicine. 2020. V. 383. №19. P. 1813-1826. https://doi.org/10.1056/nejmoa2007764
  • Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // The lancet. 2020. V. 395. №10229. P. 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
  • Zhu L., She Z. G., Cheng X., Qin J. J., Zhang X. J., Cai J., Li, H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes // Cell metabolism. 2020. V. 31. №6. P. 1068-1077. e3. https://doi.org/10.1016/j.cmet.2020.04.021
  • Bode B., Garrett V., Messler J., McFarland R., Crowe J., Booth R., Klonoff D. C. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States // Journal of diabetes science and technology. 2020. V. 14. №4. P. 813-821. https://doi.org/10.1177/1932296820924469
  • Barron E, Bakhai C, Kar P, et al. Type 1 and type 2 diabetes and COVID-19 related mortality in England: a whole population study. Available from: https://www.england.nhs.uk/wp-content/ uploads/2020/05/Valabhj i-COVID- 19-and-Diabetes-Paper-2-FullManuscript.pdf
  • Шестакова М. В., Викулова О. К., Исаков М. А., Дедов И. И. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации // Проблемы эндокринологии. 2020. Т. 66. №1. С. 35-46. https://doi.org/10.14341/probl12458
  • Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19 // Diabetes/metabolism research and reviews. 2020. V. 36. №7. P. e3319. https://doi.org/10.1002/dmrr.3319
  • Singh A. K., Gupta R., Ghosh A., Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations // Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020. V. 14. №4. P. 303-310. https://doi.org/10.1016/j.dsx.2020.04.004
  • Rao S., Lau A., So H. C. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a Mendelian randomization analysis highlights tentative relevance of diabetes-related traits // Diabetes Care. 2020. V. 43. №7. P. 14161426. https://doi.org/10.2337/dc20-0643
  • Maddaloni E., Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics //Diabetes/metabolism research and reviews. - 2020. - Т. 36. - №. 7. - С. e33213321. https://doi.org/10.1002/dmrr.3321
  • Kulcsar K. A., Coleman C. M., Beck S. E., Frieman M. B. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection // JCI insight. 2019. V. 4. №20. https://dx.doi.org/10.1172%2Fjci.insight.131774
  • Kajiwara C., Kusaka Y., Kimura S., Yamaguchi T., Nanjo Y., Ishii Y., Tateda K. Metformin mediates protection against Legionella pneumonia through activation of AMPK and mitochondrial reactive oxygen species // The Journal of Immunology. 2018. V. 200. №2. P. 623-631. https://doi.org/10.4049/jimmunol.1700474
  • Mendy A., Gopal R., Alcorn J. F., Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin // Respirology. 2019. V. 24. №7. P. 646651. https://doi.org/10.1111/resp.13486
  • Dalan R. Metformin, neutrophils and COVID-19 infection // Diabetes research and clinical practice. 2020. V. 164. https://doi.org/10.1016/j.diabres.2020.108230
  • Sharma S., Ray A., Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes // Diabetes research and clinical practice. 2020. V. 164. P. 108183. https://dx.doi.org/10.1016%2Fj.diabres.2020.108183
  • Singh A. K., Singh R. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? // Diabetes research and clinical practice. 2020. V. 165. https://doi.org/10.1016/j.diabres.2020.108268
  • EL-Arabey A. A., Abdalla M. Metformin and COVID-19: A novel deal of an Old Drug // Journal of medical virology. 2020. V. 92. №11. P. 2293-2294. https://doi.org/10.1002/jmv.25958
  • Pal R., Bhadada S. K. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? // Diabetes research and clinical practice. 2020. V. 163. https://doi.org/10.1016/j.diabres.2020.108146
  • Esam Z. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19 // Diabetes Research and Clinical Practice. 2020. V. 167. https://doi.org/10.1016/j.diabres.2020.108282
  • Kow C. S., Hasan S. S. Metformin use amid coronavirus disease 2019 pandemic // Journal of medical virology. 2020. V. 92. №11. P. 2401-2402. https://doi.org/10.1002/jmv.26090
  • Penlioglou T., Papachristou S., Papanas N. COVID-19 and diabetes mellitus: may old anti-diabetic agents become the new philosopher's stone? // Diabetes Therapy. 2020. V. 11. P. 11951197. https://doi .org/10.1007/s13300-020-00830-0
  • Ursini, F., Ciaffi, J., Landini, M. P., & Meliconi, R. COVID-19 and diabetes: Is metformin a friend or foe? // Diabetes research and clinical practice. 2020. V. 164. https://doi.org/10.1016/j.diabres.2020.108167
  • Bramante C., Ingraham N., Murray T., Marmor S., Hoversten S., Gronski J., Tignanelli C. J. Observational study of metformin and risk of mortality in patients hospitalized with Covid-19 // Medrxiv. 2020. https://doi.org/10.1101/2020.06.19.20135095
  • Chen Y., Yang D., Cheng B., Chen J., Peng A., Yang C., Huang K. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication // Diabetes care. 2020. V. 43. №7. P. 1399-1407. https://doi.org/10.2337/dc20-0660
  • Luo P., Qiu L., Liu Y., Liu X. L., Zheng J. L., Xue H. Y., Li J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis // The American journal of tropical medicine and hygiene. 2020. V. 103. №1. P. 69-72. https://doi.org/10.4269/ajtmh.20-0375
  • Bornstein S. R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A. L., Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19 // The lancet Diabetes & endocrinology. 2020. https://doi.org/10.1016/S2213-8587(20)30152-2
  • Menendez J. A. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19 // Aging (Albany NY). 2020. V. 12. №10. P. 8760. https://dx.doi.org/10.18632%2Faging.103347
  • Zumla A., Hui D. S., Azhar E. I., Memish Z. A., Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option // The Lancet. 2020. V. 395. №10224. P. e35-e36. https://doi.org/10.1016/S0140-6736(20)30305-6
  • Schuiveling M., Vazirpanah N., Radstake T. R., Zimmermann M., Broen J. C. Metformin, a new era for an old drug in the treatment of immune mediated disease? // Current drug targets. 2018. V. 19. №8. P. 945-959. https://doi.org/10.2174/1389450118666170613081730
  • Шестакова М. В., Мокрышева Н. Г., Дедов И. И. Сахарный диабет в условиях вирусной пандемии COVID-19: особенности течения и лечения // Сахарный диабет. 2020. Т. 23. №2. С. 132-139. https://doi.org/10.14341/DM12418
  • De Jager J., Kooy A., Lehert P., Wulffelé M. G., Van der Kolk J., Bets D., Stehouwer C. D. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial // Bmj. 2010. V. 340. https://doi.org/10.1136/bmj .c2181
  • Tamura J., Kubota K., Murakami H., Sawamura M., Matsushima T., Tamura T., Naruse T. Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment // Clinical & Experimental Immunology. 1999. V. 116. №1. P. 28-32. https://doi.org/10.1046/j.1365-2249.1999.00870.x
  • Al-Salameh A., Lanoix J. P., Bennis Y., Andrejak C., Brochot E., Deschasse G., Lalau, J. D. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes // Diabetes/metabolism research and reviews. 2021. V. 37. №3. P. e3388. https://doi .org/10.1002/dmrr.3388
  • Chen Y., Gu F., Guan J. L. Metformin might inhibit virus through increasing insulin sensitivity // Chinese medical journal. 2018. V. 131. №3. P. 376. https://dx.doi.org/10.4103%2F0366-6999.223856
  • Park J. W., Lee J. H., Park Y. H., Park S. J., Cheon J. H., Kim W. H., Kim T. I.Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients // World journal of gastroenterology. 2017. V. 23. №28. P. 5196. https://dx.doi.org/10.3748%2Fwjg.v23.i28.5196
  • Kelly B., Tannahill G. M., Murphy M. P., O'Neill L. A. Metformin inhibits the production of reactive oxygen species from NADH: ubiquinone oxidoreductase to limit induction of interleukin-1ß (IL-1ß) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages // Journal of biological chemistry. 2015. V. 290. №33. P. 20348-20359. https://doi.org/10.1074/jbc.M115.662114
  • Matsiukevich D., Piraino G., Lahni P., Hake P. W., Wolfe V., O'Connor M., Zingarelli B.Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock // Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017. V. 1863. №10. P. 2680-2691. https://doi.org/10.1016Zj.bbadis.2017.05.027
  • Mackey E., Ayyadurai S., Pohl C. S., D'Costa S., Li Y., Moeser A. J. Sexual dimorphism in the mast cell transcriptome and the pathophysiological responses to immunological and psychological stress // Biology of sex differences. 2016. V. 7. №1. P. 1-19. https://doi.org/10.1186/s13293-016-0113-7
  • Klein S. L., Flanagan K. L. Sex differences in immune responses // Nature Reviews Immunology. 2016. V. 16. №10. P. 626. http://dx.doi.org/10.1038/nri.2016.90
  • Li M. Y., Li L., Zhang Y., Wang X. S.Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues // Infectious diseases of poverty. 2020. V. 9. P. 1-7. https://doi.org/10.1186/s40249-020-00662-x
  • Berlin D. A., Gulick R. M., Martinez F. J. Severe covid-19 // New England Journal of Medicine. 2020. V. 383. №25. P. 2451-2460. https://doi.org/10.1056/NEJMcp2009575
  • Mehta P., McAuley D. F., Brown M., Sanchez E., Tattersall R. S., Manson J. J. COVID-19: consider cytokine storm syndromes and immunosuppression // The lancet. 2020. V. 395. №10229. P. 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp